Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of YKYY029 Injection in adults with mild to moderate hypertension
CTR20261322Phase 2Active
- Sponsor
- Yuekang Kechuang
- Start
- Apr 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of YKYY029 in hypertension (HTN), sponsored by Yuekang Kechuang. Started Apr 2026; status: active.
02
Drugs
YKYY029
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on CTR20261322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261322.